LOMBARD, Ill., June 25 /PRNewswire/ -- Orochem Technologies Inc., a leading provider of reagents and devices that serves the bioanalysis, drug discovery, genomics and proteomics markets today announced the acquisition of Oligonet, Inc. a Custom Oligonucleotide Synthesis Business located in Gaithersburg, MD. With this acquisition, Orochem will become a significant player in the custom oligo synthesis market having already been supporting oligonucleotide synthesis establishment with several products that range from synthesis plates to CPG (controlled pore glass) columns as well as having proprietary technologies for the purification of small and large scale oligonucleotides.
"We saw great synergy between the Orochem and Oligonet products and this acquisition helps us offer a complete line of products to our customers," said Dr. Asha Oroskar, President and CEO of Orochem Technologies. "We were looking for an organization that apart from providing growth to our existing businesses also understood our business and our goal of customer satisfaction."
About Oligonet: Oligonet has been serving customers in the NIH region for over 10 years with large variety of synthetic oligodeoxynucleotides (DNA), RNA, as well as oligonucleotides labeled with multiple modifications and dyes.
About Orochem: Founded in 1996, Orochem provides products and services that support academic, government research institutions, pharmaceutical and biotech companies with sample preparation products from single to high throughput formats exemplified by DNA and RNA purification kits, protein purification plates and products for bioanalysis, and oligo nucleotide synthesis and purification. The company's core expertise is in the development of customized individual and high throughput Sample Preparation tools that span liquid handling, parallel synthesis, parallel purification, and parallel processing. For further information visit www.orochem.com.